Erschienen in:
31.01.2018
Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
verfasst von:
Rohit Moudgil, Parag A. Parekh
Erschienen in:
Heart Failure Reviews
|
Ausgabe 2/2018
Einloggen, um Zugang zu erhalten
Abstract
Biomarkers are at the cornerstone of preventive measures and contribute to the screening process. More recently, biomarkers have been used to gauge the biological response to the employed therapies. Since it is ubiquitously used to detect subclinical disease process, biomarkers also have found its place in cancer therapy related cardiac dysfunction (CTRCD). The aim of this review is to comprehensively present up-to-date knowledge of biomarkers in CTRCD and highlight some of the future biomedical technologies that may strengthen the screening process, and/or provide new insight in pathological mechanisms behind CTRCD.